Monalisha Debnath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Monalisha Debnath has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Rohit Srivastava
Catalysis Research Laboratory, Department of Chemistry, Indian Institute of Technology Ropar, Rupnagar-140001, India
10 shared publications - Satyajit Saha
Department of Speciality Chemicals Technology, Institute of Chemical Technology (ICT), Mumbai, Maharashtra-400019, India
5 shared publications Chinmay Thakkar
Department of Speciality Chemicals Technology, Institute of Chemical Technology (ICT), Mumbai, Maharashtra-400019, India
4 shared publicationsPurav Badani
Department of Chemistry, University of Mumbai, Kalina Campus, Mumbai, Maharashtra, India
4 shared publications- Sangita Bose
School of Physical Sciences, UM-DAE Centre for Excellence in Basic Sciences, Mumbai, Maharashtra, India
4 shared publications Anjali Tripathi
Department of Chemistry, University of Mumbai, Kalina Campus, Mumbai, Maharashtra, India
3 shared publications
Latest Publications
- 20 November 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 23 (1)
Beyond Melanogenesis: Does PAX3 Control Reversible Melanocyte Stem-Cell States?
- 20 November 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 23 (1)
Beyond Melanogenesis: Does PAX3 Control Reversible Melanocyte Stem-Cell States?
- 5 November 2026
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-21
Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management
1. IntroductionAndrogenetic alopecia (AGA) is the most common cause of chronic progressive hair loss in both genders and is still one of the most common causes of consultation in dermatology. Altho...
- 5 November 2026
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-21
Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management
1. IntroductionAndrogenetic alopecia (AGA) is the most common cause of chronic progressive hair loss in both genders and is still one of the most common causes of consultation in dermatology. Altho...
- 29 October 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (41) , 19789-19805
Distortion-driven AIE design: a multimodal platform for designing high-efficiency OLEDs, fluorescent photosensitizers for ROS-mediated theranostics and cancer cell imaging
Deliberate incorporation of a spirofluorene-cored imidazo[1,2- a ]pyridine framework yields a multifunctional AIE-active luminogen that combines the high EQE max performance of OLEDs with potent photosensitizing capability and bio-imaging applications.
- 29 October 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (41) , 19789-19805
Distortion-driven AIE design: a multimodal platform for designing high-efficiency OLEDs, fluorescent photosensitizers for ROS-mediated theranostics and cancer cell imaging
Deliberate incorporation of a spirofluorene-cored imidazo[1,2- a ]pyridine framework yields a multifunctional AIE-active luminogen that combines the high EQE max performance of OLEDs with potent photosensitizing capability and bio-imaging applications.
- 3 September 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (8) , 3832-3834
Beyond Growth Factor Abundance: Why Hair Regeneration Needs Pathway-Oriented Design?
- 3 September 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (8) , 3832-3834
Beyond Growth Factor Abundance: Why Hair Regeneration Needs Pathway-Oriented Design?
- 29 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (12) , 5065-5081
Twist and charge transfer modulation in imidazo[1,2- a ]pyridine encapped 1,3,5-triazine towards multifunctional green-emissive DSEgens: applications in TNP sensing, bioimaging, and organic light emitting diodes
Charge and twist modulation across triazine acceptor using imidazo[1,2- a ]pyridine donors towards achieving multifunctional dual state emissive emitters for TNP sensing, cell-imaging and green OLED.
- 29 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (12) , 5065-5081
Twist and charge transfer modulation in imidazo[1,2- a ]pyridine encapped 1,3,5-triazine towards multifunctional green-emissive DSEgens: applications in TNP sensing, bioimaging, and organic light emitting diodes
Charge and twist modulation across triazine acceptor using imidazo[1,2- a ]pyridine donors towards achieving multifunctional dual state emissive emitters for TNP sensing, cell-imaging and green OLED.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
Peripheral acceptor modulation in designing multifunctional imidazo[1,2- a ]pyridine-derived AIEgens for applications in sensing (metal/TNP), cell-imaging and OLEDs
The quest for high-performance solid-state luminogens continues to motivate the design of next-generation emitters capable of overcoming the limitations imposed by aggregation-caused quenching (ACQ).
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
Peripheral acceptor modulation in designing multifunctional imidazo[1,2- a ]pyridine-derived AIEgens for applications in sensing (metal/TNP), cell-imaging and OLEDs
The quest for high-performance solid-state luminogens continues to motivate the design of next-generation emitters capable of overcoming the limitations imposed by aggregation-caused quenching (ACQ).
- 15 April 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (21) , 10576-10591
Balancing the molecular twist and conformational rigidity in imidazo[1,2- a ]pyridines to achieve dual-state emissive (DSE) luminogens for applications in OLEDs and cell-imaging
An effective design strategy for creating imidazo[1,2- a ]pyridine-derived luminogens is proposed, offering a dependable avenue for building TADF-DSE materials for applications in OLEDs and cell imaging.
- 15 April 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (21) , 10576-10591
Balancing the molecular twist and conformational rigidity in imidazo[1,2- a ]pyridines to achieve dual-state emissive (DSE) luminogens for applications in OLEDs and cell-imaging
An effective design strategy for creating imidazo[1,2- a ]pyridine-derived luminogens is proposed, offering a dependable avenue for building TADF-DSE materials for applications in OLEDs and cell imaging.
- 7 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (8) , 3955-3968
Engineering of imidazo[1,2- a ]pyridine into multifunctional dual-state emissive (DSE) luminogens for hydrazine sensing and cell-imaging
Balancing the donor–acceptor (D–A) systems and spatial configurations to precisely modulate dual-state emission (DSE) properties in imidazo[1,2- a ]pyridine-derived luminogens for applications in cell imaging and hydrazine sensing.
- 7 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (8) , 3955-3968
Engineering of imidazo[1,2- a ]pyridine into multifunctional dual-state emissive (DSE) luminogens for hydrazine sensing and cell-imaging
Balancing the donor–acceptor (D–A) systems and spatial configurations to precisely modulate dual-state emission (DSE) properties in imidazo[1,2- a ]pyridine-derived luminogens for applications in cell imaging and hydrazine sensing.
- Open Access
- 18 October 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1389
Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications
Hypoxia is a crucial factor in tumor biology, affecting various solid tumors to different extents. Its influence spans both early and advanced stages of cancer, altering cellular functions and promoting resistance to therapy. Hypoxia reduces the effectiveness of radiotherapy, chemotherapy, and immunotherapy, making it a target for improving therapeutic outcomes. Despite extensive research, gaps persist, necessitating the exploration of new chemical and pharmacological interventions to modulate hypoxia-related pathways. This review discusses the complex pathways involved in hypoxia and the associated pharmacotherapies, highlighting the limitations of current treatments. It emphasizes the potential of nanoparticle-based platforms for delivering anti-hypoxic agents, particularly oxygen (O2), to the tumor microenvironment. Combining anti-hypoxic drugs with conventional cancer therapies shows promise in enhancing remission rates. The intricate relationship between hypoxia and tumor progression necessitates novel therapeutic strategies. Nanoparticle-based delivery systems can significantly improve cancer treatment efficacy by targeting hypoxia-associated pathways. The synergistic effects of combined therapies underscore the importance of multimodal approaches in overcoming hypoxia-mediated resistance. Continued research and innovation in this area hold great potential for advancing cancer therapy and improving patient outcomes.
- 18 October 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1389
Open AccessTargeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications
Hypoxia is a crucial factor in tumor biology, affecting various solid tumors to different extents. Its influence spans both early and advanced stages of cancer, altering cellular functions and promoting resistance to therapy. Hypoxia reduces the effectiveness of radiotherapy, chemotherapy, and immunotherapy, making it a target for improving therapeutic outcomes. Despite extensive research, gaps persist, necessitating the exploration of new chemical and pharmacological interventions to modulate hypoxia-related pathways. This review discusses the complex pathways involved in hypoxia and the associated pharmacotherapies, highlighting the limitations of current treatments. It emphasizes the potential of nanoparticle-based platforms for delivering anti-hypoxic agents, particularly oxygen (O2), to the tumor microenvironment. Combining anti-hypoxic drugs with conventional cancer therapies shows promise in enhancing remission rates. The intricate relationship between hypoxia and tumor progression necessitates novel therapeutic strategies. Nanoparticle-based delivery systems can significantly improve cancer treatment efficacy by targeting hypoxia-associated pathways. The synergistic effects of combined therapies underscore the importance of multimodal approaches in overcoming hypoxia-mediated resistance. Continued research and innovation in this area hold great potential for advancing cancer therapy and improving patient outcomes.